Literature DB >> 2651132

Dexamethasone in neonatal chronic lung disease: pulmonary effects and intracranial complications.

C M Noble-Jamieson1, R Regev, M Silverman.   

Abstract

Eighteen infants were entered into a randomized, placebo-controlled trial of dexamethasone therapy for chronic lung disease. Initial ventilation requirements were similar in the two groups, although all infants were in headbox oxygen on entry to the trial. The dexamethasone-treated infants showed a significantly more rapid improvement during the 1st week of treatment, although the overall duration of oxygen therapy was similar in both groups. Cranial ultrasound examination revealed new periventricular abnormalities in three out of the five dexamethasone-treated infants who had previously normal scans, compared with none of four similar placebo-treated infants. A large trial, focussing on potential complications, is now needed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2651132     DOI: 10.1007/bf00444135

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  3 in total

1.  Dexamethasone and increased intracranial echogenicity.

Authors:  R Regev; L S de Vries; C M Noble-Jamieson; M Silverman
Journal:  Lancet       Date:  1987-03-14       Impact factor: 79.321

2.  Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia.

Authors:  G B Avery; A B Fletcher; M Kaplan; D S Brudno
Journal:  Pediatrics       Date:  1985-01       Impact factor: 7.124

3.  Morbidity and survival in neonates ventilated for the respiratory distress syndrome.

Authors:  A Greenough; N R Roberton
Journal:  Br Med J (Clin Res Ed)       Date:  1985-02-23
  3 in total
  14 in total

1.  Respiratory and systemic effects of inhaled dexamethasone on ventilator dependant preterm infants at risk for bronchopulmonary dysplasia.

Authors:  M Pappagallo; S Abbasi; V K Bhutani
Journal:  Indian J Pediatr       Date:  1998 Mar-Apr       Impact factor: 1.967

Review 2.  A risk-benefit assessment of drugs used for neonatal chronic lung disease.

Authors:  D G Sweet; H L Halliday
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

Review 3.  Bronchopulmonary dysplasia: early diagnosis, prophylaxis, and treatment.

Authors:  A Greenough
Journal:  Arch Dis Child       Date:  1990-10       Impact factor: 3.791

Review 4.  Effects of antenatal and postnatal corticosteroids on the preterm lung.

Authors:  J Vyas; S Kotecha
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-09       Impact factor: 5.747

Review 5.  Drug utilisation in preterm and term neonates.

Authors:  L Gortner
Journal:  Pharmacoeconomics       Date:  1993-12       Impact factor: 4.981

Review 6.  The effectiveness and side effects of dexamethasone in preterm infants with bronchopulmonary dysplasia.

Authors:  P C Ng
Journal:  Arch Dis Child       Date:  1993-03       Impact factor: 3.791

Review 7.  Chronic lung disease of prematurity: are we too cautious with steroids?

Authors:  M Silverman
Journal:  Eur J Pediatr       Date:  1994       Impact factor: 3.183

8.  Early postnatal dexamethasone treatment and increased incidence of cerebral palsy.

Authors:  E S Shinwell; M Karplus; D Reich; Z Weintraub; S Blazer; D Bader; S Yurman; T Dolfin; A Kogan; S Dollberg; E Arbel; M Goldberg; I Gur; N Naor; L Sirota; S Mogilner; A Zaritsky; M Barak; E Gottfried
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-11       Impact factor: 5.747

9.  Growth retardation after dexamethasone administration: assessment by knemometry.

Authors:  A T Gibson; R G Pearse; J K Wales
Journal:  Arch Dis Child       Date:  1993-11       Impact factor: 3.791

Review 10.  Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.

Authors:  Lex W Doyle; Jeanie L Cheong; Richard A Ehrenkranz; Henry L Halliday
Journal:  Cochrane Database Syst Rev       Date:  2017-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.